Objective: This study aims to evaluate the associations of early menopause (menopause occurring before age 45 years) and age at menopause with incident heart failure (HF) in postmenopausal women. We also explored the associations of early menopause and age at menopause with left ventricular (LV) measures of structure and function in postmenopausal women.
P rior studies have investigated the relationship between menopause and cardiovascular disease (CVD) 1<3 ; however, the results have been inconsistent, and the direct causal relationship between menopause and increased cardiovascular risk is still being debated. 4 Early menopause (menopause occurring before age 45 years) has been linked to increased cardiovascular risk, 4 and age at menopause may be an indicator of biologic aging. 2 The increase in cardiovascular risk at menopause may be a consequence of estrogen deprivation 3<5 or may result from a higher prevalence of cardiovascular risk factors, such as hypertension, 3, 6 diabetes, 3, 4, 7, 8 visceral obesity, 4, 7, 9 insulin resistance, 7,8 dyslipidemia, 3, 4, 7, 8 and endothelial dysfunction, 4 that occur with aging. 3 Amidst ongoing studies investigating the relationship between menopause and CVD, the association between age at menopause and heart failure (HF) is yet to be investigated. Sex-related differences in the anatomy and physiology of the myocardium have been found, 10 and there could also be differences in HF between women and men. HF with preserved ejection fraction or diastolic dysfunction occurs more commonly in women than in men. 5, 11 Estrogen has multiple effects on the cardiovascular system, 5, 12 and its deficiency may contribute to sex differences in the pathogenesis and progression of CVD, 8, 10 including HF in the postmenopausal period.
Studies involving small sample sizes have indicated that menopause may be associated with impaired left ventricular (LV) systolic and diastolic cardiac functions. 13<16 However, the relationship between age at menopause and LV measures of structure and function has not been studied in large population-based cohorts. We evaluated the associations of early menopause and age at menopause with incident HF in postmenopausal women enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). We also explored the associations of early menopause and age at menopause with LV measures of structure and function obtained by magnetic resonance imaging (MRI) in MESA postmenopausal women at baseline.
METHODS

Study population
MESA is a population-based cohort of 6,814 participants (including 3,601 women)Vaged 45 to 84 years (2000) (2001) (2002) and without clinical CVD at baselineVof white (38%), African-American (28%), Chinese (12%), and Hispanic (22%) descent. The aim of MESA was to study the characteristics of subclinical CVD and risk factors that predict progression to clinically overt CVD or progression of the subclinical disease. Participants were enrolled from six locations in the United States. MESA's design and objectives have been published. 17 The protocol was approved by institutional review boards at participating centers, and informed consent was obtained from participants. This substudy included 2,949 postmenopausal women and used baseline and HF data collected and adjudicated as of October 2012. We had a sample size of 2,947 after excluding two women who were missing information on their HF status.
Baseline measurements
Standardized questionnaires were used to collect information on menopause, age at menopause, ethnicity, educational status, cigarette smoking, number of pregnancies, history of oophorectomy, use of hormone therapy (HT), hypertension, diabetes, and medications. Women were asked if they had gone through Bmenopause[ or Bchange of life[ and required to state the age at which they experienced menopause. Women who reported that they were going through menopause at baseline were asked to provide the date of their last menstrual period and the number of periods they had experienced in the last 12 months. Women who did not experience menstruation for 12 months or more before baseline were classified as being postmenopausal. Participants were classified as having early menopause if they experienced menopause before age 45 years. Weight was measured to the nearest 0.5 kg using a balance scale. Height was measured to the nearest 0.1 cm using a stadiometer. Body mass index (BMI) was calculated as weight divided by the square of height (kg/m 2 ) and used to indicate generalized obesity. Waist and hip circumferences were measured to the nearest 0.1 cm, using a measuring tape, at the umbilicus and maximal hip diameter, respectively. Waist-to-hip ratio (WHR) was calculated by dividing waist circumference by hip circumference and used to indicate visceral obesity. 18 Three measurements of resting blood pressure (BP) were obtained using a Dinamap automated sphygmomanometer, and the mean of the second and third readings was used. Hypertension was defined as systolic BP of 140 mm Hg or higher, diastolic BP of 90 mm Hg or higher, or use of antihypertensive medications.
Fasting plasma glucose and insulin levels were measured using glucose oxidase and radioimmunoassay methods, respectively. 19, 20 Diabetes was defined as a fasting glucose level of 126 mg/dL or higher or use of hypoglycemic medications. 20 Insulin resistance (indicated by homeostasis model assessment for insulin resistance [HOMA-IR]) was calculated as: fasting glucose (mmol/L) Â fasting insulin (KU/mL) / 22.5. 20 Triglycerides and high-density lipoprotein cholesterol (HDL-C) were measured with a glycerol-blanked enzymatic method and cholesterol-oxidase reaction, respectively, using fasting plasma samples. 19 Metabolic syndrome is the clinical surrogate of insulin resistance 21 and is defined, according to the National Cholesterol Education Program Adult Treatment Panel III, as consisting of three or more of the following metabolic abnormalities: central obesity (waist circumference 9102 cm in men and 988 cm in women), high triglycerides (Q150 mg/dL), low HDL-C (G40 mg/dL in men and G50 mg/dL in women), high BP (Q130/85 mg/dL) or being on antihypertensive medications, and high fasting blood glucose (Q100 mg/dL) or being on antidiabetic medications. 22 Interleukin-6 was the inflammatory marker with the strongest prediction for incident HF in MESA 20 and was measured using an ultrasensitive enzyme-linked immunosorbent assay. 23 Serum creatinine measured by colorimetry was used to determine creatinine-based estimated glomerular filtration rate, which is an indicator of kidney function. 24 Resting 12-lead electrocardiograms were obtained, centrally read, and coded for the presence of LV hypertrophy (LVH) using the Minnesota coding system.
Cardiac MRI performed with 1.5-T magnets was obtained in a subset of MESA participants at baseline and was available for 2,123 postmenopausal women. Imaging data were read with MASS software, version 4.0 (Medis, Leiden, The Netherlands). MESA cardiac MRI protocol, image analysis, and inter-reader and intrareader reproducibility have been reported. 25 LV mass (LVM) was calculated as the summation of the myocardial area multiplied by slice thickness plus image gap in the end-diastolic phase multiplied by the myocardial specific gravity. LV enddiastolic volume (LVEDV) and LV end-systolic volume were determined by summing the myocardial areas on each separate slide multiplied by the sum of slice thickness and image gap. LV mass-to-volume ratio (LVMVR) was derived by dividing LVM by LVEDV. LV stroke volume (LVSV) was derived by subtracting LV end-systolic volume from LVEDV. LV ejection fraction (LVEF) was calculated by dividing LVSV by LVEDV and multiplying by 100. Details of quality control activities that were conducted at MESA field centers, coordinating centers, laboratories, and electrocardiogram and MRI reading centers are available in the manual of operations at www.mesa-nhlbi.org.
Follow-up and incident HF definition
The median follow-up was 8.5 years (interquartile range, 0.96), with 22,598 person-years of observation. Each participant or the next of kin was contacted by a telephone interviewer at 6-to 9-month intervals to inquire about interim hospitalizations, outpatient diagnoses, and deaths due to cardiovascular causes. 20 Records were obtained on approximately 99% of hospitalized cardiovascular encounters, and some information was obtained on 97% of outpatient diagnostic encounters. Hospital records were abstracted and reviewed by paired physicians for independent endpoint classification and assignment of incidence dates. 20 The reviewing pair adjudicated differences. If disagreements persisted, the morbidity and mortality classification committee made the final decision.
Our endpoint was new-onset HF. Multiple HF occurrences in the same participant were considered once, and the time to the first event was used. Endpoint criteria for HF in MESA included the following: (1) physician-diagnosed HF and medical therapy for HF and (2) pulmonary edema/congestion on chest radiography, or (3) dilated ventricle or poor LV function on echocardiography or ventriculography, or evidence of LV diastolic dysfunction. 20 Participants not meeting HF criteria and those with a physician diagnosis only (without any other evidence) were classified as not having HF. Myocardial infarction (MI) is a potent HF risk factor 26 and was diagnosed based on the presence of symptoms, electrocardiographic findings, and cardiac biomarker levels. 20 
Statistical analysis
Data are presented according to postmenopausal group, using mean (SD) or median (interquartile range) for continuous variables and percentage for categorical variables. We calculated the incidence rates of HF per 1,000 person-years of exposure in each postmenopausal group. Owing to skewness, logarithmic transformation was performed for triglycerides, interleukin-6, HOMA-IR, and number of pregnancies. Comparisons between postmenopausal groups were tested using W 2 test (categorical variables), t test (normally distributed continuous variables), and Mann-Whitney U test (nonYnormally distributed continuous variables). We also compared postmenopausal women according to their incident HF status. Kaplan-Meier plots for incident HF are presented according to postmenopausal group and tested with log-rank test. Participants were censored if they were lost to follow-up or if they failed to experience incident HF at the end of follow-up.
We assessed the hazard ratios of incident HF for early menopause and every 1-year increase in age at menopause using Cox proportional hazards models. We checked for interactions of early menopause and age at menopause with ethnicity for incident HF at the 0.05 significance level. We constructed unadjusted models (model 1) and age-adjusted models (model 2). In model 3, we introduced ethnicity, center, reproductive characteristics (number of pregnancies and use of HT), and known HF risk factors, 20,26<29 including socioeconomic status (indicated by educational status), smoking, hypertension, diabetes, kidney function, obesity (indicated by BMI), LVH (by electrocardiogram), insulin resistance, inflammation, and interim MI. Because we included its individual components, metabolic syndrome was excluded. Owing to our modest number of HF events, we selected the most parsimonious model using backward elimination, in which age was retained and variables were eliminated if their P 9 0.10. The resulting model included early menopause (or age at menopause), age, smoking, BMI, diabetes, hypertension, LVH, and interim MI. Participants with missing data on a variable needed for a particular model were excluded from analyses. We checked for proportionality of hazards by visually examining log-log plots.
In exploration, we conducted cross-sectional analysis in postmenopausal women who had cardiac MRI at baseline. Because LV measures in MESA have been found to differ by ethnicity, 30 we calculated age-adjusted means of LV measures according to ethnicity, postmenopausal group, and HT use with analysis of covariance. LV measures were also adjusted for height and weight to account for the confounding effects of body size. 18 LVEF and LVMVR were only age-adjusted. We calculated adjusted differences in LV measures attributable to early menopause and every 1-year increase in age at menopause using multivariable linear regression. We tested for the presence of interactions of early menopause and age at menopause with ethnicity for all LV measures at the 0.05 significance level. We present ethnicity-stratified analyses because we observed significant interactions between early menopause and ethnicity for LVMVR (P interaction = 0.02). We adjusted for known potential confounders, height, weight, reproductive characteristics, and HF risk factors. Height and weight were excluded from models for LVEF and LVMVR. BMI was excluded from models that included height and weight to avoid colinearity. We checked for linearity by visually examining the scatterplots of R-Student residuals versus predicted values.
We performed a sensitivity analysis of the MRI cohort, in which we assessed the hazard ratios of incident HF for early menopause and every 1-year increase in age at menopause in models that replaced LVH, determined by electrocardiogram with its corresponding MRI equivalent. In a subpopulation of 822 men and women without LVH risk factors in MESA, the 95th percentile cutoff of the observed/predicted LVM of 1.31 has been accepted as corresponding to LVH. 31 Two-sided P G 0.05 was considered significant. Statistical analysis was performed using SAS enterprise guide version 4.3 (SAS Institute Inc, Cary, NC).
RESULTS
There were 195 cases (118 in men and 77 in women) of incident HF in MESA. We observed 71 events in our sample of postmenopausal women, and 25 events occurred in women who experienced early menopause. The overall HF incidence among MESA postmenopausal women was 3.14 per 1,000 person-years, with incidences of 4.57 and 2.69 per 1,000 personyears in women who experienced and did not experience early menopause, respectively. The HF incidence was 2.93, 2.23, 4.02, and 2.92 per 1,000 person-years in white, Chinese-American, African-American, and Hispanic postmenopausal women, respectively (Table 1, Supplemental Digital Content 1, http://links.lww.com/MENO/A78). Early menopause was reported by 730 participants. Women who experienced early menopause were more commonly African American and current smokers and attained lower educational levels at baseline. Interleukin-6, BMI, and HOMA-IR levels were higher, and diabetes was more prevalent in women who experienced early menopause (Table 1 ). Twenty-one women experienced MI before their HF diagnosis. There were no statistically significant differences in the occurrence of interim MI across postmenopausal groups. Postmenopausal women who developed incident HF had lower glomerular filtration rates but higher BMI, WHR, HOMA-IR, and interleukin-6 levels. Hypertension, diabetes, and LVH were more prevalent among participants who developed incident HF. All participants who experienced MI during followup subsequently developed incident HF ( Table 2 , Supplemental Digital Content 2, http://links.lww.com/MENO/A79). The probability of being free from HF was significantly less in women who experienced early menopause (Fig. 1 ). There were no significant interactions with ethnicity for incident HF (P interaction 9 0.05). In adjusted analysis, early menopause was associated with an increased risk of incident HF, whereas every 1-year increase in age at menopause was associated with a decreased risk of incident HF ( Table 2) . For our exploratory analysis of the MRI cohort, we had 2,123 postmenopausal women, 509 of whom had experienced early menopause. The MRI cohort included 840 white, 272 Chinese-American, 558 African-American, and 453 Hispanic women. Adjusted means of LVMVR were higher whereas LVEDV was lower in Chinese-American women who experienced early menopause who were not using HT at baseline ( In adjusted analysis, early menopause was associated with higher LVMVR and lower LVSV and LVEDV, whereas every 1-year increase in age at menopause was associated with lower LVMVR and higher LVSV and LVEDV in Chinese Americans (Table 3 ). There was no significant colinearity because the variance inflation factors and condition indices were less than 5 for all terms in each of the models. In sensitivity analyses of the MRI cohort, in which LVH determined by electrocardiogram A total of 2,123 postmenopausal women obtained cardiac magnetic resonance imaging at baseline, and 509 had experienced menopause before age 45 years. Estimates are differences (A-coefficients) associated with every 1-year increase in age at menopause and between the early menopausal group and the nonYearly menopausal group. Estimates are adjusted for age, height, weight, educational status, cigarette smoking, center, number of pregnancies, use of hormone therapy, diabetes, highdensity lipoprotein cholesterol, triglycerides, waist-to-hip ratio, homeostasis model assessment for insulin resistance, interleukin-6, creatinine-based estimate of glomerular filtration rate, systolic blood pressure, diastolic blood pressure, and antihypertensive medication use. MESA, Multi-Ethnic Study of Atherosclerosis. was replaced with its MRI equivalent, the hazard ratios (95% CIs) of incident HF were 1.46 (0.71-2.98) and 0.97 (0.93-1.01) for early menopause and every 1-year increase in age at menopause, respectively, after adjusting for age, smoking, BMI, diabetes, hypertension, LVH, and interim MI. However, we observed only 39 events in the MRI cohort and had inadequate power to make definitive conclusions related to incident HF. Postmenopausal women who had a cardiac MRI at baseline were younger, were more educated, and had lower BMI and WHR than those who did not have a cardiac MRI (Table 4 , Supplemental Digital Content 4, http://links.lww.com/MENO/A81). Diabetes and hypertension were more prevalent among women who did not have a cardiac MRI at baseline. The percentage of missing data was less than 3% for all variables; therefore, sample sizes may have varied slightly between the models.
DISCUSSION
In this multiethnic population of postmenopausal women, we have shown that older age at menopause is associated with a decreased risk of incident HF. This association remained significant after adjusting for chronological age and known HF risk factors. This finding suggests that menopause may have independent effects on the heart and that a later age at menopause could delay the onset of this deleterious effect. Estrogen deficiency is pathognomonic of the postmenopausal period. 7, 9 Consequently, the relationships of early menopause and age at menopause with incident HF could be explained by changes in the duration of exposure to endogenous estrogen.
Menopause is associated with metabolic derangements 3,8,9 such as lipid abnormalities, visceral obesity, and insulin resistance, which are known HF risk factors. 27, 29, 32, 33 Women who experienced early menopause in our study had worse metabolic profiles with an increased prevalence of diabetes, generalized obesity, insulin resistance, and higher inflammatory markers. The reason behind these metabolic changes remains controversial because menopause is a normal consequence of aging, 7 which is associated with an increased prevalence of cardiometabolic risk factors. 3 The higher LVMVR (which indicates LV concentric remodeling) 18 and lower LVSV (which is a determinant of cardiac output) observed in Chinese-American women who experienced early menopause at baseline may be attributable to their lower LVEDV measures. However, in white, African-American, and Hispanic women, we did not observe differences in LV measures attributable to early menopause or every 1-year increase in age at menopause at baseline. Our findings for Chinese-American women agree with the study by Kaur et al, 14 in which subclinical cardiac dysfunction was reported in women with earlier onset of menopause but differed for white, African-American, and Hispanic women. These similarity and differences may be related to the different ethnicities of the populations being studied, but the ethnicity of participants in the study by Kaur et al was not specified. Moreover, the study of Kaur et al included 50 participants and obtained LV measures by echocardiography. We used LV measures obtained by MRI, which is more accurate. 18 We did not observe ethnic differences in the relationships of early menopause and age at menopause with incident HF. Thus, we concluded that the association with incident HF was consistent across ethnic groups. Because Chinese-American women who experienced early menopause exhibited evidence of concentric remodeling at baseline, we speculated that they possibly manifested subclinical cardiac effects of estrogen deficiency due to menopause sooner than other ethnicities. However, this hypothesis must be explored in future studies. Despite the ethnic differences observed in the association with LVMVR at baseline, the consistency in the association between age at menopause and incident HF across all ethnicities after a median follow-up of 8.5 years could imply that the effects of menopause (and possibly estrogen deficiency) are progressive across time.
The cardiac effects of estrogen are both direct and indirect and are mediated by estrogen receptor-> and estrogen receptor-A. 4, 34 The direct effects include rapid vasodilatation through increased nitric oxide production 5, 12, 34, 35 and longerterm effects involving genomics-mediated changes in the expression of proteins that regulate vascular tone and response to injury. 12, 34 Estrogen-mediated genomic effects increase vasodilatory enzymes and accelerate endothelial cell growth 34 but inhibit smooth muscle proliferation, collagen, and elastin deposition. 10, 34 Indirect effects include actions on ventricular contractile function, endothelial calcium metabolism and coronary calcification, coagulation and fibrinolysis, insulin resistance, inflammation, oxidative alterations in lipids, and changes in lipid profile. 4, 10, 34 Estrogen increases serum levels of HDL-C and triglycerides and decreases low-density lipoprotein cholesterol and low-density lipoprotein cholesterol oxidation. 34 Estrogen also modulates cardiac myocyte sensitivity to autonomic stimuli and results in enhanced inotropy, decreased chronotropy, and reduced cardiac respiratory and energy needs. 10 These effects support a myocardium-protective role for estrogens, which is lost after the onset of menopause.
To the best of our knowledge, our study is the first to demonstrate the associations of early menopause and age at menopause with incident HF. Other strengths of our study include its prospective nature, the availability of a multiethnic sample without clinical CVD at baseline, and highly standardized data collection methods. Our study has limitations. Estrogen levels were not measured at baseline. The postmenopausal period is also associated with changes in ovarian androgen production and a state of relative androgen predominance. 9 Circulating androgen levels were not measured at baseline. Age at menopause was based on self-report, and variations in the onset and abruptness of menopause 36 could lead to recall bias. However, reliability and validity studies have shown that women can recall their age at menopause with accuracy. 37 Owing to a modest number of events, we had inadequate power for analysis according to HF subtypes (HF preserved ejection fraction or reduced ejection fraction) or type of menopause (natural or artificial). Surgical menopause due to oophorectomy was reported by 783 women. However, we had no information on artificial menopause due to chemotherapy, radiotherapy, autoimmune illness, or pelvic infections. Electrocardiography has limited sensitivity for diagnosing LVH. 31 Because of sample size limitations, we used the full sample and electrocardiographic measurements of LVH for our primary analysis. We adjusted for interim MI, but the absence of MI does not exclude subclinical myocardial ischemia. Only few women who experienced early menopause were taking HT at baseline; thus, we had limited power to present our fully adjusted models for LV measures in the MRI cohort according to HT use. We had inadequate power for our sensitivity analysis related to incident HF in the MRI cohort; thus, caution must be applied to interpretations related to this sensitivity analysis.
CONCLUSIONS
Older age at menopause is associated with a decreased risk of incident HF. Concentric LV remodeling indicated by higher LVMVR was present in Chinese-American women who experienced early menopause at baseline. It is debatable whether the cardiac changes that result in HF in the postmenopausal period are primarily caused by aging or result from estrogen deficiency. However, age at menopause may be an indicator of increased HF risk and signals a need for more frequent screening and aggressive risk factor modification.
